On February 20, 2018 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, reported that it will release fourth quarter and full year 2017 financial results after the market closes on Tuesday, February 27, 2018 (Press release, Xencor, FEB 20, 2018, View Source [SID1234524357]). Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers, and referencing conference ID number 3991218. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company’s website located at View Source The webcast will be archived on the company website for 30 days.

On February 20, 2018 Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported that it has received a recommendation by the Independent Data Monitoring Committee (DMC) to continue patient enrollment of its ongoing Phase 2 Clinical Trial for HS-110 and nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC) (Press release, Heat Biologics, FEB 20, 2018, View Source [SID1234524070]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The recommendation follows the first of several planned DMC meetings that took place on Wednesday, Feb. 14, 2018, to discuss the continued development of the trial.

"We believe that the continued advisement from an independent, unbiased committee of expert clinicians will help guide us to select the most appropriate patient population to include in a registrational trial for NSCLC," said CEO of Heat, Jeff Wolf. "We look forward to expanding enrollment to additional patient cohorts who may benefit from our therapy."

To-date, 35 adenocarcinoma patients with no prior history with checkpoint inhibitors have been treated with the HS-110/nivolumab combination. Further enrollment is expected to also include patients with squamous cell histology as well as those who have relapsed after checkpoint inhibitor therapy.

Heat will be hosting an analyst and investor event in New York City on February 28, 2018, at 8 a.m. ET, to discuss data generated from the first 35 patients enrolled in this trial. Event details and webcast information to be provided prior to the event.

On February 20, 2018 Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 "Lodonal" and IRT-101 "MENK") for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs, reported the company has shipped its initial order of Lodonal to AHAR Pharma in Nigeria (Press release, Immune Therapeutics, FEB 20, 2018, View Source [SID1234524071]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, IMUN has received both trademark and patent approval from the Federal Republic of Nigeria giving the Company ironclad protection of its ideas, inventions, designs, and trade secrets while also ensuring IMUN legal rights are not infringed upon.

Immune Therapeutics shipped 100,000 capsules of Lodonal fulfilling the initial purchase order for $195,000 with AHAR Pharma, Immune’s agent and distributor in Nigeria. Since the company’s shipment has recently cleared customs, it is now available via AHAR in Nigeria.

The company has received a Certificate of Patent Approval for Lodonal NG/P/2017/602 and Certificate of Registration of Design (Trademark, Name, Box Design) NG/D.2017/603.

CEO Noreen Griffin states, "The initial Lodonal order to Nigeria is just the beginning for us with many more to come based on our strong relationship with AHAR and our ability to expand our reach in the African country through a number of potential sub-distributors for sales and marketing."

"While we are focused on an aggressive marketing strategy of Lodonal in Nigeria it is vital for us to register and protect our intellectual property rights there as well especially due to the fact that we are a non-Nigerian business desiring to take a slice of the almost 200 Million strong import-dependent domestic market which Nigeria represents. We also believe it forestalls potential pirating and counterfeiting of our products as well."

"Immune and AHAR are currently completing the necessary regulatory paperwork for presentation to the National Agency for Food and Drug Administration and Control (NAFDAC) for the approval of Lodonal for a number of additional indications."

Griffin said she believes the company will be ready to submit to NAFDAC in Q1 of 2018.

The company plans to meet this month with AHAR, GB Pharma and Fidson HealthCare as a follow up to their initial meeting in October, 2017. The companies plan to further discuss the potential for the transfer of distributorship from AHAR to Fidson. Under a potential new agreement, AHAR would remain Immune’s agent in Nigeria.

On February 20, 2018 Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or the "Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, reported allowance of a key patent application from the European Patent Office (EPO) covering a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union (Press release, Propanc, FEB 20, 2018, View Source [SID1234524077]). The allowed patent application is the first approval for the Company in the EU, which protects the Company’s lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to make significant progress with respect to building our intellectual property portfolio, which is an important cornerstone for biotech companies like ours," said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. "In addition to our lead patent application, we also have three patents entering national phase this year and another patent application currently under preparation. It is a promising sign that we are advancing a world class portfolio covering a new therapeutic approach using pancreatic proenzymes for the treatment and prevention of metastatic cancer from solid tumors."

Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company’s initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.

To view Propanc Biopharma’s "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: View Source

To be added to Propanc Biopharma’s email distribution list, please click on the following link: View Source and submit the online request form.

On February 20, 2018 INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, reported that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will present at the RBC Capital Markets Global Healthcare Conference as follows (Press release, Insys Therapeutics, FEB 20, 2018, View Source [SID1234524107]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, Feb. 22, 2018
Time: 10:00 a.m. Eastern Standard Time
Location: Lotte New York Palace Hotel

The presentation will be webcast live at the aforementioned time, and archived for 90 days thereafter, via the Investors section of company’s website at View Source, under Presentations & Events. Accessible at the same webpage, the presentation slides will be available during and after the conference.

In addition to making a presentation, management will also provide an overview of the company’s business in one-on-one meetings with investors who are registered to attend the conference.